Kilohertz e-tns stimulation

The device for external trigeminal nerve stimulation with specific pulse parameters addresses the limitations of existing treatments by reducing discomfort and enhancing efficacy for headaches and neurological disorders through high-frequency, low-discomfort stimulation.

JP2024167443AInactive Publication Date: 2024-12-03CEFALY TECH SPRL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024158996
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-18
Filing Date
2024-09-13
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing treatments for headaches, particularly migraines, often cause discomfort due to paresthesias and are ineffective for patients with frontal cutaneous allodynia, and existing devices for trigeminal nerve stimulation have limitations in frequency and efficacy.

Method used

A device and method for external trigeminal nerve stimulation (e-TNS) using continuous electrical pulses with a frequency of 0.5 kHz to 50 kHz, pulse width of 1 microsecond to 500 microseconds, and amplitude of 0.1mA to 200mA, specifically targeting the supratrochlear and supraorbital nerves, which reduces or avoids paresthesias by utilizing high-frequency stimulation during the refractory period of nerve activity.

Benefits of technology

The proposed solution effectively treats headaches and neurological disorders by minimizing discomfort and improving treatment efficacy for patients, including migraines, by avoiding paresthesias through optimized pulse parameters.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167443000001_ABST
    Figure 2024167443000001_ABST
Patent Text Reader

Abstract

To provide a device and a method for the abortive or preventive treatment of a headache via external trigeminal nerve stimulation, in particular, transcutaneous non-invasive electrical trigeminal stimulation via consecutive pulses.SOLUTION: Pulses 102 include: a pulse repetition frequency 123 of 0.5 kilohertz to 50 kilohertz; a pulse width 121 of 1 microsecond to 500 microseconds; and a pulse amplitude 111 of 0.1 milliampere to 200 milliamperes.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Content of disclosure

[0001] [Technical field] The present invention relates to the technical field of devices and methods for the abortive or prophylactic treatment of headaches via transcutaneous electrical nerve stimulation (TENS), in particular external trigeminal nerve stimulation (e-TNS).

[0002] 〔background〕 Headaches, especially migraines, can significantly impair quality of life. Acute treatment is primarily a pharmacological approach, with the most commonly used drugs being analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans. These drugs have several contraindications and are associated with moderate to severe side effects. Excessive intake can lead to headache chronification, medication overuse headache and / or resistance.

[0003] Neurostimulation has been shown to be a good alternative to pharmacological approaches and is suitable for both acute and preventative treatment.

[0004] WO2016 / 155773 A1 and US Patent Publication No. 2018 / 0056065 A1 disclose a device for percutaneous electrical stimulation of the trigeminal nerve, in particular the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve, configured to generate rectangular biphasic pulses with a width of 2 μs to 500 μs, a frequency of 1 Hz to 250 Hz, and an intensity of 1 mA to 25 mA.

[0005] Riederer, Penning and Schoenen, “Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly Device for Migraine Prevention: A review of the Available Data”, Pain and Therapy 4(2), pages 135-147 (2015), doi:10.1007 / s40122-015-0039-5, discloses e-TNS of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve via the following rectangular biphasic electrical impulses: Electrical mean value equal to 0; · Impulse width of 250 microseconds; A frequency of 60 Hertz; and 16mA maximum intensity.

[0006] By acting on the nerves, e-TNS produces paresthesia in the forehead and / or skull, which some patients find unpleasant. In addition, some migraine patients suffer from frontal cutaneous allodynia. Combined with frontal cutaneous allodynia, the paresthesia induced by e-TNS is very painful, which makes e-TNS treatment of such patients impossible.

[0007] Solomon and Guglielmo, “Treatment of Headache by Transcutaneous Electrical Stimulation”, Headache 25(1), pages 12-15 (1985), doi:10.1111 / j.1526-4610.1985.hed2501012.x, disclose TENS via monophasic pulses with amperage up to 4 mA, frequencies between 12 kHz and 20 kHz, and durations of approximately 30 μs. This article does not describe trigeminal nerve stimulation.

[0008] US Patent Application Publication No. 2010 / 0030299 A1 discloses a battery-powered TENS unit for treating headaches interruptively and / or prophylactically. The document discloses comb electrodes placed on the occipital region. The document discloses monophasic pulses with frequency / width: 3 kHz / 50 μs and 10 kHz / 40 μs, among other combinations. The document further discloses spaced rectangular biphasic pulse trains with a frequency of 1 kHz and biphasic pulse widths of 275 or 475 μs, among other examples. The output current can be limited via a series resistor to a maximum of 10 mA or 5 mA, among other values. The device according to this document is not suitable for trigeminal nerve stimulation.

[0009] An object of the present invention is to solve at least part of the above problems.

[0010] Summary of the Invention In a first aspect, the present invention provides a device for the abortive or prophylactic treatment of headache via external trigeminal nerve stimulation (e-TNS) as claimed in claim 1.

[0011] In a second aspect, the present invention provides a train of electrical pulses for use in abortive or prophylactic electrotherapy treatment of headache via transcutaneous non-invasive electrical trigeminal nerve stimulation as claimed in claim 16.

[0012] In a third aspect, the present invention provides a train of electrical pulses for use in electrotherapy treatment of neurological disorders via transcutaneous non-invasive electrical trigeminal nerve stimulation as claimed in claim 17.

[0013] In a fourth aspect, the present invention provides a method for the abortive or prophylactic treatment of headache via e-TNS as claimed in claim 18.

[0014] In a fifth aspect, the present invention provides the use of a device according to the first aspect for electrotherapy treatment of a neurological disorder, as claimed in claim 20.

[0015] Each embodiment differs from WO2016 / 155773, US2018 / 0056065 A1 and Riederer (2015) in at least the pulse repetition frequency, which is between 0.5 kilohertz and 50 kilohertz (i.e., 500 hertz to 50,000 hertz), i.e., significantly higher than the frequencies disclosed in WO2016 / 155773, US2018 / 0056065 A1 and Riederer (2015).

[0016] Certain treatment parameters have the advantageous technical effect of mitigating or avoiding paresthesia during external trigeminal nerve stimulation.

[0017] Without being bound by theory, the applicant believes that this may be due to the following reasons: After an action potential, membrane pumps change the ion (Na+ and K+) permeability of the nerve membrane, restoring the rest potential required to make the nerve cell excitable again. If the repetition frequency of the impulses is high enough, impulses are fired during the refractory period after the action potential, and although they cannot generate new action potentials, they are sufficient to maintain the depolarization of the cell and prevent the recovery of the rest polarization, so that the nerve cell cannot induce action potentials and paresthesia. [Brief description of the drawings]

[0018] [Figure 1] 1 illustrates an embodiment of a series of pulses. [Diagram 2] 1 illustrates an embodiment of a series of pulses. [Diagram 3] 1 illustrates an embodiment of a series of pulses. [Figure 4] 1 illustrates an embodiment of a series of pulses. [Diagram 5] 1 illustrates an embodiment of a series of pulses. [Figure 6A] 1 shows an embodiment of a power supply fixture for a device according to the invention; [Figure 6B] 1 shows an embodiment of a power supply fixture for a device according to the invention; [Figure 7] 1 shows an embodiment of an electrode piece of a device according to the invention applied to the supraorbital region of a person's forehead. [Figure 8] 8 shows a free-standing device attached to a person's forehead according to the embodiment of FIGS. 6A, 6B and 7. FIG.

[0019] Detailed Description of the Invention The present invention relates to devices and methods for the abortive or prophylactic treatment of headaches via external trigeminal nerve stimulation (e-TNS), and the use of the devices for the electrotherapeutic treatment of neurological disorders.

[0020] Unless otherwise defined, all terms used in disclosing the present invention, including technical and scientific terms, have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. By way of further guidance, term definitions are included to better understand the teachings of the present invention.

[0021] As used herein, the following terms have the following meanings.

[0022] As used herein, "a," "an," and "the" refer to both singular and plural referents unless the context clearly dictates otherwise. By way of example, "a compartment" refers to one or more than one compartment.

[0023] "About" as used herein with reference to a measurable value, such as a parameter, amount, temporal duration, and the like, is meant to include a variation of no more than + / -20%, preferably no more than + / -10%, more preferably no more than + / -5%, even more preferably no more than + / -1%, and even more preferably no more than + / -0.1% of the particular value, insofar as such variations are appropriate for the practice of the disclosed invention, although it is to be understood that the value to which the modifier "about" refers is itself also specifically disclosed.

[0024] As used herein, "Comprise," "comprising," and "comprises," as well as "comprised of," are synonymous with "include," "including," "includes," or "contain," "containing," or "contains," and are inclusive or open-ended terms that specify the presence of what follows, e.g., a component, and do not exclude or preclude the presence of additional, unrecited components, features, elements, materials, or steps that are known or disclosed in the art.

[0025] The recitation of numerical ranges by endpoints includes not only the recited endpoints but also all numbers and fractions subsumed within that range.

[0026] In a first aspect, the present invention provides a device for the abortive or prophylactic treatment of headaches via e-TNS, the device being configured for non-invasive transcutaneous electrical nerve stimulation (TENS) of the trigeminal nerve via a train of pulses comprising: Pulse repetition frequency from 0.5 kHz to 50 kHz; · Pulse width from 1 microsecond to 500 microseconds; Pulse amplitudes from 0.1mA to 200mA.

[0027] In a second aspect, the present invention provides a train of electrical pulses for use in abortive or prophylactic electrotherapy treatment of headaches via transcutaneous non-invasive electrical trigeminal nerve stimulation. The train of pulses comprises: Pulse repetition frequency from 0.5 kHz to 50 kHz; · Pulse width from 1 microsecond to 500 microseconds; Pulse amplitudes from 0.1mA to 200mA.

[0028] In a third aspect, the present invention provides a train of electrical pulses for use in electrotherapy treatment of neurological disorders via transcutaneous non-invasive electrical trigeminal nerve stimulation. The train of pulses comprises: Pulse repetition frequency from 0.5 kHz to 50 kHz; · Pulse width from 1 microsecond to 500 microseconds; Pulse amplitudes from 0.1mA to 200mA.

[0029] In a fourth aspect, the present invention provides a method for the abortive or prophylactic treatment of headaches via e-TNS. The method comprises the steps of non-invasive TENS of the trigeminal nerve via a train of pulses. The train of pulses comprises: Pulse repetition frequency from 0.5 kHz to 50 kHz; · Pulse width from 1 microsecond to 500 microseconds; Pulse amplitudes from 0.1mA to 200mA.

[0030] The device according to the first aspect may be used in preventive or abortive electrotherapy treatment of headaches. Thus, the invention may also relate to a device according to the first aspect for use in preventive or abortive electrotherapy treatment of headaches.

[0031] The device according to the first aspect can be used for electrotherapy treatment of neurological disorders. Thus, the present invention also relates to a device according to the first aspect for use in electrotherapy treatment of neurological disorders. The present invention also relates to the use of a device according to the first aspect for electrotherapy treatment of neurological disorders.

[0032] In a preferred embodiment, the neurological disorder is selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial neuropathy, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress syndrome, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and cerebellar syndrome.

[0033] e-TNS has so far been shown to be very effective in the treatment of headaches, especially migraines. This treatment can be performed via non-invasive TENS, which can be performed completely non-invasively, i.e. without surgery, as opposed to transcutaneous methods that require electrode insertion. The applicant has surprisingly discovered that certain treatment parameters of the present invention avoid or reduce paresthesia during treatment. Without being bound by theory, the applicant believes that this can be attributed to the following reasons: After an action potential, a membrane pump changes the ion (Na+ and K+) permeability of the nerve membrane, restoring the resting potential necessary to make the nerve cell excitable again. If the repetition frequency of the impulses is high enough, the impulses are fired during the refractory period after the action potential, and cannot generate a new action potential, but are sufficient to maintain the depolarization of the cell and prevent the restoration of the resting polarization, so that the nerve cell cannot induce action potentials and paresthesia.

[0034] A person skilled in the art will understand that the device according to the first aspect may be configured to deliver successive pulses according to the second and / or third aspect. A person skilled in the art will further understand that the device according to the first aspect may be configured to perform the method according to the fourth aspect, and the method according to the fourth aspect may be performed by the device according to the first aspect. Thus, the different aspects of the present invention are interrelated. Thus, each feature described above and below may be related to each aspect of the present invention, even if it is described in relation to a specific aspect.

[0035] As used herein, "treatment parameters" refers to the pulse repetition frequency f and / or the pulse repetition period T p , pulse amplitude, pulse width T w and treatment time T t The characteristics of successive pulses include: the pulse amplitude is the maximum absolute amplitude; the pulse repetition frequency is the inverse of the average pulse repetition period of the successive pulses.

[0036] In a preferred embodiment, the device, the train of pulses and / or the method is configured for transcutaneous electrical nerve stimulation (TENS) of the supra-orbital nerve and the supratrochlear nerve of the ophthalmic branch of the trigeminal nerve via train of pulses.Preferably, the device, the train of pulses and / or the method is configured for non-invasive TENS of the afferent pathway of the supra-trochlear nerve and the supra-orbital nerve of the ophthalmic branch of the trigeminal nerve via train of pulses.This is advantageous because these nerves can be easily stimulated via non-invasive TENS via skin parts, typically the forehead of a person, more specifically the supra-orbital region, which is typically hairless or contains a small amount of hair, allowing easy application and removal of electrodes.

[0037] In a preferred embodiment, the pulse is a rectangular pulse.

[0038] In a preferred embodiment, two successive pulses contain a net charge transfer of at most 1 picocoulomb, preferably at most 0.1 picocoulomb, more preferably at most 0.01 picocoulomb, even more preferably at most 0.001 picocoulomb, and most preferably essentially no net charge transfer, i.e. essentially 0.0 picocoulomb net charge transfer.

[0039] In a preferred embodiment, the rectangular biphasic pulse comprises two successive pulses that are both rectangular and monophasic. The first pulse comprises a first amplitude A1 that is essentially constant for a first pulse width T1. The second pulse, which is later in time than the first pulse, comprises a second amplitude A2 that is essentially constant for a second pulse width T2. The second amplitude comprises an opposite sign to the constant first amplitude, i.e. A1.A2<0.

number

number

number

[0040] The non-limiting examples shown in Figures 1-4 illustrate several aspects of a pulse train and are not intended, nor should they be construed, to limit the scope of the invention.

[0041] FIG. 1 shows several successive pulses on a two-dimensional graph including an amplitude axis (101) and a time axis (100). The amplitude (112) indicates that no current is being transmitted, i.e., an amplitude of 0.0 milliamps. The pulses (102) have a pulse width T w (121) and pulse repetition period T p(123), both of which are time parameters. The pulse repetition period T p (123) and pulse width T w Difference from (121) g =T p -T w (122) is the time gap from the previous pulse to the next pulse. The pulse repetition frequency is f=1 / T p The pulse further includes a pulse amplitude A (111). The pulse may be rectangular, thereby having a pulse width T, as in FIG. w The applied current signal may be continuous. Thus, the pulses may be, for example, triangular or sinusoidal.

[0042] FIG. 2 shows several successive pulses on a two-dimensional graph including an amplitude axis (101) and a time axis (100). The amplitude (312) indicates no current transfer, i.e., an amplitude of 0.0 milliamps. The two successive pulses (302, 303) contain essentially a net charge transfer of 0.0 picocoulombs. The rectangular, gapped, biphasic pulses include a first monophasic rectangular pulse (302) and a second monophasic rectangular pulse (303). The first pulse (302) has a pulse width T 1,w (321), amplitude A1 (311), and time gap T until the second pulse 1,g (322). The second pulse (303) has a pulse width T 2,w (324) and amplitude A2 (313), where A1 and A2 have opposite phases, i.e. A1.A2<0. The second pulse is followed by a time gap T 2,g (325) is included. Pulse repetition period T p (330) is the biphasic pulse repetition period, i.e., the time span between the start of two consecutive rectangular biphasic pulses. The pulse repetition frequency is f=1 / T p The two successive pulses (302, 303) involve essentially zero net charge transfer, i.e.

number

number

[0043] FIG. 3 shows several successive pulses on a two-dimensional graph including an amplitude axis (101) and a time axis (100). The amplitude (512) indicates no current transfer, i.e., an amplitude of 0.0 milliamps. Two successive triangular pulses (502, 503) contain essentially a net charge transfer of 0.0 picocoulombs. The symmetrical triangular, gapped biphasic pulses include a first monophasic triangular pulse (502) and a second monophasic triangular pulse (503). The first pulse (502) has a pulse width T 1,w (521), amplitude A1 (511), and time gap T until the second pulse 1,g (522). The second pulse (503) has a pulse width T 2,w (524) and amplitude A2 (513), where A1 and A2 are in antiphase, i.e. A1.A2<0. The second pulse is followed by a time gap T 2,g (525). Pulse repetition period T p (530) is the biphasic pulse repetition period, i.e., the time span between the start of two consecutive biphasic pulses. The pulse repetition frequency is f=1 / T p It can be calculated as: The time gap between the first and second pulses may or may not be equal. The pulse widths of the first and second pulses are equal since biphasic pulses are symmetric. The pulse amplitudes, i.e., absolute values ​​of the amplitudes, of the first and second pulses are equal since biphasic pulses are symmetric.

[0044] FIG. 4 shows several successive pulses on a two-dimensional graph including an amplitude axis (101) and a time axis (100). The amplitude (712) indicates no current transfer, i.e., an amplitude of 0.0 milliamps. Two successive sinusoidal pulses (702, 703) contain a net charge transfer of essentially 0.0 picocoulombs. The symmetrical sinusoidal, gapped, biphasic pulses include a first monophasic sinusoidal pulse (702) and a second monophasic sinusoidal pulse (703). The first pulse (702) has a pulse width T 1,w (721), amplitude A1 (711), and time gap T until the second pulse 1,g (722). The second pulse (703) has a pulse width T 2,w (724) and amplitude A2 (713), where A1 and A2 have opposite phases, i.e. A1.A2<0. The second pulse is followed by a time gap T 2,g (725) is included. Pulse repetition period T p (730) is the biphasic pulse repetition period, i.e., the time span between the start of two consecutive biphasic pulses. The pulse repetition frequency is f=1 / T p It can be calculated as: The time gap of the first and second pulses may or may not be equal. The pulse width of the first and second pulses is equal since biphasic pulses are symmetric. The pulse amplitude, i.e., the absolute value of the amplitude, of the first and second pulses is equal since biphasic pulses are symmetric.

[0045] In a preferred embodiment, the pulse repetition frequency is between 2 kHz and 40 kHz. The pulse repetition frequency is preferably at least 4 kHz, more preferably at least 6 kHz, even more preferably at least 7 kHz, even more preferably at least 8 kHz, and most preferably at least 9 kHz. The pulse repetition frequency is preferably at most 30 kHz, more preferably at most 24 kHz, even more preferably at most 20 kHz, even more preferably at most 16 kHz, more preferably at most 14 kHz, even more preferably at most 12 kHz, and most preferably at most 11 kHz. In a particularly preferred embodiment, the pulse repetition frequency is about 10 kHz.

[0046] In a preferred embodiment, the pulse width is between 4 microseconds and 240 microseconds, preferably between 8 microseconds and 120 microseconds, more preferably between 12 microseconds and 60 microseconds, even more preferably between 16 microseconds and 50 microseconds, even more preferably between 20 microseconds and 40 microseconds, and most preferably between 25 microseconds and 35 microseconds. In a particularly preferred embodiment, the pulse width is about 30 microseconds.

[0047] In a preferred embodiment, the pulse amplitude is between 1 and 128 mA, preferably between 2 and 64 mA, more preferably between 4 and 32 mA, even more preferably between 5 and 16 mA, and most preferably between 6 and 12 mA. In a particularly preferred embodiment, the pulse amplitude is about 8 mA.

[0048] In preferred embodiments, the treatment time is at least 5 minutes, preferably at least 10 minutes, more preferably at least 15 minutes, even more preferably at least 20 minutes, even more preferably at least 25 minutes, more preferably at least 30 minutes, even more preferably at least 40 minutes, even more preferably at least 45 minutes, and most preferably at least 60 minutes.

[0049] In a preferred embodiment, the device according to the first aspect and the method according to the fourth aspect comprise a treatment time, preferably of at least 5 minutes, of: Pulse repetition frequency of 8 kHz to 12 kHz; · Pulse width from 12 microseconds to 60 microseconds; Pulse amplitude from 5mA to 16mA; The device can be configured for non-invasive TENS of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve via rectangular pulses comprising, preferably, two successive pulses comprising a net charge transfer of at most 0.1 picocoulombs.

[0050] In a preferred embodiment, the device is configured to increase, preferably linearly increase, the pulse amplitude at a rate of up to 480 microamps / second before the treatment. In a preferred embodiment, the method includes a step of increasing, preferably linearly increase, the pulse amplitude at a rate of up to 480 microamps / second before the treatment step. The rate is preferably up to 240 microamps / second, more preferably up to 120 microamps / second, even more preferably up to 60 microamps / second, even more preferably up to 30 microamps / second, and most preferably up to 15 microamps / second. In a particularly preferred embodiment, the rate is about 9.5 microamps / second. Preferably, the increase is made during a start-up time span of at least 4 minutes, preferably at least 6 minutes, more preferably at least 8 minutes, even more preferably at least 10 minutes, and most preferably at least 12 minutes. The pulse amplitude then remains essentially constant for the duration of the treatment. This is advantageous since it allows for a gradual habituation to the amplitude of the treatment during the start-up phase before the treatment.

[0051] The non-limiting examples shown in FIG. 5 illustrate some aspects of actuation and are not intended, nor should they be construed, to limit the scope of the invention.

[0052] FIG. 5 shows several successive symmetrical biphasic rectangular pulses during start-up on a two-dimensional graph including an amplitude axis (101) and a time axis (100). The amplitude (912) indicates no current delivery, i.e., an amplitude of 0.0 milliamps. Each biphasic pulse includes a first pulse (902, 902', 902", 902''') and a second pulse (903, 903', 903", 903'") that include successively larger pulse amplitudes (911, 911', 911", 911''') over the subsequent biphasic pulses. The increase in pulse amplitude was linear in this case. The first pulse (902) has a pulse width T 1,w (921) and the time gap T until the second pulse 1,g (922). The second pulse (903) has a pulse width T 2,w (924) and the time gap T 2,g (925) and the pulse frequency is f=2 / (T 1,p +T 2,p ) The time gap of the first and second pulses may or may not be equal. The pulse width of the first and second pulses is equal since the biphasic pulses are symmetric. The pulse repetition period T p (930) is the biphasic pulse repetition period, i.e., the time span between the start of two consecutive rectangular biphasic pulses. The pulse repetition frequency is f=1 / T p It can be calculated as:

[0053] In a preferred embodiment, the device is portable and configured to be self-supporting on the person's forehead. The portable device may include an electrode piece and a power supply device. The power supply device may be configured to be manually attached to and manually detached from the electrode piece. The electrode piece may include a pair of spaced apart self-adhesive conductive gel zones for attachment to the person's forehead. Preferably, the power supply device is configured to be manually attached to and manually detached from the electrode piece via at least two engaging pairs of metallic contacts. These engaging pairs of metallic contacts are thereby further configured to establish an electrical connection between the power supply device and the pair of spaced apart self-adhesive conductive gel zones. Preferably, the engaging pairs of metallic contacts include snap buttons or magnets. Preferably, the electrode piece is configured to be attached to the supraorbital region of the person's forehead, thereby covering the afferent pathways of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve.

[0054] In a preferred embodiment, the apparatus includes a power delivery apparatus configured to determine an impedance for current transfer, whereby the power delivery apparatus is further configured to discontinue treatment when an impedance above a predetermined threshold is determined.

[0055] In a preferred embodiment, the device includes at least one physiological sensor and is configured to discontinue therapy and / or adapt one or more therapy parameters based at least in part on a signal obtained from the at least one physiological sensor.

[0056] In a preferred embodiment, the device includes a power supply apparatus configured to maintain a battery. The power supply apparatus can maintain the battery. The battery can be rechargeable. The power supply apparatus can include a USB port for recharging the battery. The USB port can also allow for transferring treatment parameters to the power supply apparatus and / or receiving information about the treatment session from the power supply apparatus. The power supply apparatus can include a non-contact recharging module for inductively or capacitively recharging the battery.

[0057] The non-limiting examples shown in Figures 6A-8 illustrate certain mechanical aspects of one embodiment of a device in accordance with the present invention and are not intended, nor should they be construed as limiting the scope of the invention.

[0058] Figures 6A and 6B show an embodiment of a power supply attachment of a device according to the invention. Figure 7 shows an embodiment of an electrode piece (30) of a device according to the invention attached to the supraorbital region (20) of a person's forehead. Figure 8 shows a free-standing device attached to a person's forehead, including a power supply attachment according to Figures 6A and 6B and an electrode piece according to Figure 7.

[0059] The power supply device comprises an upper part (2) and a lower part (3) which are securable relative to one another. The lower part (3) comprises a control opening (5) through which at least one control means (5'), e.g. a button, may protrude. The lower part (3) further comprises two magnet openings (6) through each of which a magnet (6') may protrude. The lower part (3) also comprises a micro USB opening (7) through which a micro USB port (7') may protrude.

[0060] The electrode piece (30) includes a front side and a back side. On the back side (not shown), the electrode piece (30) includes a pair of spaced apart self-adhesive conductive gel zones for application to a person's forehead. On the front side, the electrode piece (30) includes a pair of metal contacts, preferably magnetic metal contacts, including a relative distance that corresponds to a magnet opening (6) of a power supply device. Each metal contact is electrically connected to a self-adhesive conductive gel zone. The device is configured to removably attach a power supply device to the electrode piece via the magnets and metal contacts.

[0061] The top (2) and bottom (3) provide an interior space for housing a printed circuit board (PCB) (10) and a battery (11). A mechanical movement of the control means (5') may be transferred to the PCB (10) via an intermediate part (5"), said mechanical movement being converted into a suitable impedance (resistance, capacitance, inductance), voltage and / or current change. The battery (11) may be connected to the PCB (10) via at least two wires (12). The PCB includes two contact blades (6") configured to hold the battery against the PCB and further configured each to contact a magnet (6').

[0062] The PCB further includes a microcontroller unit (15) and a tangible, non-transitory computer readable storage medium. A micro USB port allows for recharging the battery and transferring treatment parameters and / or other information to and / or from the power supply.

[0063] PCB: Determining the impedance between the blades (6') or between a pair of self-adhesive conductive gel zones; Aborting treatment when impedance outside a predetermined region of interest (e.g., resistance above a predetermined threshold) is determined during initiation or treatment; It is configured as follows.

[0064] [Embodiment] (1) A device for the abortive or prophylactic treatment of headache via external trigeminal nerve stimulation, the device comprising: Pulse repetition frequency from 0.5 kHz to 50 kHz; Pulse widths between 1 microsecond and 500 microseconds; and Pulse amplitude from 0.1mA to 200mA, The device is configured for transcutaneous non-invasive electrical trigeminal nerve stimulation via a train of pulses including: (2) The device of embodiment 1, wherein the device is configured for percutaneous, non-invasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve via the pulses. (3) The apparatus of any one of claims 1 to 2, wherein the pulse is a rectangular pulse. (4) An apparatus according to any of the preceding claims, wherein two successive pulses comprise a net charge transfer of at most 1 picocoulomb, preferably at most 0.1 picocoulomb, more preferably at most 0.01 picocoulomb, even more preferably at most 0.001 picocoulomb, and most preferably essentially 0.0 picocoulomb. (5) The apparatus according to any one of embodiments 1 to 4, wherein the pulse repetition frequency is between 2 kilohertz and 40 kilohertz, the pulse repetition frequency is preferably at least 4 kilohertz, more preferably at least 6 kilohertz, even more preferably at least 7 kilohertz, even more preferably at least 8 kilohertz, and most preferably at least 9 kilohertz, and the pulse repetition frequency is preferably at most 30 kilohertz, more preferably at most 24 kilohertz, even more preferably at most 20 kilohertz, even more preferably at most 16 kilohertz, more preferably at most 14 kilohertz, even more preferably at most 12 kilohertz, and most preferably at most 11 kilohertz.

[0065] (6) The device according to any one of embodiments 1 to 5, wherein the pulse width is 8 microseconds to 120 microseconds, preferably 12 microseconds to 60 microseconds, more preferably 16 microseconds to 50 microseconds, even more preferably 20 microseconds to 40 microseconds, and most preferably 25 microseconds to 35 microseconds. (7) The apparatus according to any one of the preceding embodiments, wherein the pulse amplitude is between 1 mA and 128 mA, preferably between 2 mA and 64 mA, more preferably between 4 mA and 32 mA, even more preferably between 5 mA and 16 mA, and most preferably between 6 mA and 12 mA. (8) The device according to any of the preceding claims, wherein the successive pulses are applied during a treatment time of at least 5 minutes, preferably at least 10 minutes, more preferably at least 15 minutes, even more preferably at least 20 minutes, even more preferably at least 25 minutes, more preferably at least 30 minutes, even more preferably at least 40 minutes, even more preferably at least 45 minutes, and most preferably at least 60 minutes. (9) The device comprises: Pulse repetition frequency of 8 kHz to 12 kHz; Pulse widths between 12 microseconds and 60 microseconds; and Pulse amplitude from 5mA to 16mA; and configured for percutaneous noninvasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve via a rectangular pulse comprising: Two successive pulses contain a net charge transfer of up to 0.1 picocoulombs. A device according to any of embodiments 1 to 8 for the abortive or prophylactic treatment of headache via external trigeminal nerve stimulation. (10) The device of any of the preceding claims, wherein the device is configured to increase, preferably linearly increase, the pulse amplitude prior to the treatment at a rate of up to 480 microamps / second, preferably up to 240 microamps / second, more preferably up to 120 microamps / second, even more preferably up to 60 microamps / second, even more preferably up to 30 microamps / second, and most preferably up to 15 microamps / second.

[0066] (11) A portable device according to any one of claims 1 to 10, comprising: an electrode piece; and a power supply apparatus configured to be manually attached to and manually detached from the electrode piece, the electrode piece including a pair of spaced apart self-adhesive conductive gel zones for attachment to a forehead of a person; the device configured to be self-supporting on the forehead of the person; preferably, the power supply apparatus configured to be manually attached to and manually detached from the electrode piece via at least two pairs of engaging metal contacts further configured to establish an electrical connection between the power supply apparatus and the pair of spaced apart self-adhesive conductive gel zones; more preferably, the pair of engaging metal contacts include snap buttons or magnets. (12) The portable device of embodiment 11, wherein the electrode strip is configured to be attached to the supraorbital region of the person's forehead, thereby covering the afferent pathways of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve. (13) The device of any of embodiments 1 to 12, wherein the device includes at least one physiological sensor, and the device is configured to discontinue therapy and / or adapt one or more therapy parameters based at least in part on a signal obtained from the at least one physiological sensor. (14) A device as described in any one of embodiments 1 to 13 for use in preventive or abortive electrotherapy treatment of headaches. (15) The device according to any of embodiments 1 to 13, for use in electrotherapy treatment of a neurological disorder selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial neuropathy, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress disorder, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea syndrome, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke, and cerebellar syndrome.

[0067] (16) A train of electrical pulses for use in interruptive or prophylactic electrotherapy treatment of headache via percutaneous noninvasive electrical trigeminal nerve stimulation, preferably percutaneous noninvasive electrical nerve stimulation of the afferent pathways of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve, comprising: The series of pulses includes: Pulse repetition frequency from 0.5 kHz to 50 kHz; Pulse widths between 1 microsecond and 500 microseconds; and Pulse amplitude from 0.1mA to 200mA, A series of electrical pulses, including (17) A train of electrical pulses for use in electrotherapy treatment of neuropathy via percutaneous non-invasive electrical trigeminal nerve stimulation, preferably percutaneous non-invasive electrical nerve stimulation of the afferent pathways of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve, comprising: the neurological disorder is selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial neuropathy, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress syndrome, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and cerebellar syndrome; The series of pulses includes: Pulse repetition frequency from 0.5 kHz to 50 kHz; Pulse widths between 1 microsecond and 500 microseconds; and Pulse amplitude from 0.1mA to 200mA, A series of electrical pulses, including (18) A method for the abortive or prophylactic treatment of headache via external trigeminal nerve stimulation, comprising: A pulse repetition frequency between 0.5 kHz and 50 kHz, preferably between 8 kHz and 12 kHz; a pulse width of 1 microsecond to 500 microseconds, preferably 12 microseconds to 60 microseconds; and Pulse amplitude of 0.1mA to 200mA, preferably 5mA to 16mA; percutaneous non-invasive electrical trigeminal nerve stimulation, preferably of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve, via a train of pulses, preferably rectangular pulses, comprising: Preferably, the two successive pulses comprise a net charge transfer of at most 0.1 picocoulombs. (19) The method of embodiment 18, comprising the step of increasing, preferably linearly increasing, the pulse amplitude at a rate of up to 480 microamps / second, preferably up to 240 microamps / second, more preferably up to 120 microamps / second, even more preferably up to 60 microamps / second, even more preferably up to 30 microamps / second, and most preferably up to 15 microamps / second, prior to said step of treating. (20) Use of the device according to any of embodiments 1 to 13 for electrotherapy treatment of a neurological disorder selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial neuropathy, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress disorder, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea syndrome, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and cerebellar syndrome.

Claims

1. 1. A device for the abortive or prophylactic treatment of headache via external trigeminal nerve stimulation, the device comprising: A pulse repetition frequency of 0.5 kHz to 50 kHz; A pulse width between 1 microsecond and 500 microseconds; and Pulse amplitudes from 0.1 milliamps to 200 milliamps; and configured for transcutaneous non-invasive electrical trigeminal stimulation via a train of pulses including: the device is configured to increase the pulse amplitude at a rate of up to 480 microamps / second during a start-up period prior to the treatment; Device.

2. 10. The device of claim 1, wherein the device is configured for percutaneous non-invasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve via the pulses.

3. 3. The apparatus of claim 1, wherein the pulse is a rectangular pulse.

4. 4. An apparatus according to claim 1, wherein two successive pulses comprise a net charge transfer of at most 1 picocoulomb.

5. 5. The apparatus of claim 1, wherein the pulse repetition frequency is between 2 kHz and 40 kHz.

6. The apparatus of any one of claims 1 to 5, wherein the pulse width is between 8 microseconds and 120 microseconds.

7. 7. The apparatus of claim 1, wherein the pulse amplitude is greater than or equal to 60 milliamps and less than or equal to 128 milliamps.

8. 8. The device of claim 1, wherein the succession of pulses is applied during the treatment period of at least 5 minutes.

9. The apparatus comprises: A pulse repetition frequency of 8 kHz to 12 kHz; A pulse width between 12 microseconds and 60 microseconds; and - Pulse amplitude between 5mA and 16mA; and configured for percutaneous noninvasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve via a rectangular pulse comprising: Two successive pulses contain a net charge transfer of up to 0.1 picocoulombs.

9. A device according to any one of claims 1 to 8 for the abortive or prophylactic treatment of headaches via external trigeminal nerve stimulation.

10. 10. The device of claim 1, comprising an electrode and a power supply apparatus configured to be manually attached to and manually detached from the electrode, the electrode including a pair of spaced apart self-adhesive conductive gel zones for attachment to a person's forehead, the device configured to be self-supporting on the person's forehead.

11. 11. The device of claim 10, wherein the electrode is configured to be attached to the supraorbital region of the person's forehead, thereby covering the afferent pathways of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve.

12. 12. The device of claim 1, wherein the device includes at least one physiological sensor, the device being configured to discontinue therapy and / or adapt one or more therapy parameters based at least in part on a signal obtained from the at least one physiological sensor.

13. 13. A device according to any one of claims 1 to 12 for use in preventive or abortive electrotherapy treatment of headaches.

14. 14. The device of any one of claims 1 to 13 for use in the electrotherapy treatment of neurological disorders selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial neuropathy, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress syndrome, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and cerebellar syndrome.

15. 1. A train of electrical pulses for use in abortive or prophylactic electrotherapy treatment of headaches by transcutaneous non-invasive electrical trigeminal nerve stimulation, comprising: The series of electrical pulses includes: A pulse repetition frequency of 0.5 kHz to 50 kHz; A pulse width between 1 microsecond and 500 microseconds; and Pulse amplitudes from 0.1 milliamps to 200 milliamps; Including, The train of electrical pulses is configured to increase the pulse amplitude at a rate of up to 480 microamps / second during a start-up period prior to the treatment. A series of electrical pulses.

16. 1. A train of electrical pulses for use in electrotherapy treatment of neuropathy by transcutaneous non-invasive electrical trigeminal nerve stimulation, comprising: said neurological disorder is selected from the group consisting of migraine, tension headache, cluster headache, hemicrania continua, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), chronic paroxysmal hemicrania, trigeminal neuralgia, facial nerve disorder, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress syndrome, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive-compulsive disorder, insomnia, sleep disorders, sleep apnea, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and cerebellar syndrome; The series of electrical pulses includes: A pulse repetition frequency of 0.5 kHz to 50 kHz; A pulse width between 1 microsecond and 500 microseconds; and Pulse amplitudes from 0.1 milliamps to 200 milliamps; Including, The train of electrical pulses is configured to increase the pulse amplitude at a rate of up to 480 microamps / second during a start-up period prior to the treatment. A series of electrical pulses.

17. a conductive gel coupled to a pair of electrodes, the conductive gel configured to adhere to the patient's forehead; 15. The apparatus of any one of claims 1 to 14, further comprising a housing containing a processor and a memory, the housing releasably coupled to the pair of electrodes.

18. The apparatus of claim 17 , wherein the housing comprises a magnet configured to magnetically couple to the pair of electrodes.

19. 19. The apparatus of claim 17, wherein the housing comprises an impedance sensor and a power source, the impedance sensor configured to measure the impedance of the conductive gel or the power source.

20. 20. The apparatus of any one of claims 1 to 14 and 17 to 19, further comprising a physiological sensor coupled to a processor, the physiological sensor configured to generate a signal, and the processor configured to modify the pulse based on the signal.

21. 16. The train of electrical pulses of claim 15, wherein the abortive or prophylactic electrotherapy treatment is delivered via percutaneous non-invasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve.

22. 17. The train of electrical pulses of claim 16, wherein the electrotherapy treatment of the neuropathy is achieved via percutaneous non-invasive electrical nerve stimulation of the supratrochlear and supraorbital nerve afferent pathways of the ophthalmic branch of the trigeminal nerve.

Citation Information

Patent Citations

  • Device for transcutaneous electrical stimulation of the trigeminal nerve

    JP2018510047A

  • Method and device for transdermally applying electrical stimulation to a region of the head having high impedance

    WO2017178946A1